{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T11:06:17Z","timestamp":1784977577432,"version":"3.55.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.urology.2018.07.055","type":"journal-article","created":{"date-parts":[[2018,9,13]],"date-time":"2018-09-13T13:45:51Z","timestamp":1536846351000},"page":"120-126","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Utilization of Bacillus Calmette-Guerin for Nonmuscle Invasive Bladder Cancer in an Era of Bacillus Calmette-Guerin Supply Shortages"],"prefix":"10.1016","volume":"124","author":[{"given":"Abhinav","family":"Khanna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Yerram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Abouassaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2018.07.055_bib0001","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2018.07.055_bib0002","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.6004\/jnccn.2017.0156","article-title":"Bladder cancer, Version 5.2017, NCCN clinical practice guidelines in oncology","volume":"15","author":"Spiess","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.urology.2018.07.055_bib0003","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","article-title":"EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016","volume":"71","author":"Babjuk","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2018.07.055_bib0004","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1464-410X.2003.04655.x","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials","volume":"93","author":"Shelley","year":"2004","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2018.07.055_bib0005","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ctrv.2009.12.005","article-title":"Intravesical therapy for superficial bladder cancer: a systematic review of randomised trials and meta-analyses","volume":"36","author":"Shelley","year":"2010","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.urology.2018.07.055_bib0006","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","article-title":"An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Gu\u00e9rin for non-muscle-invasive bladder cancer","volume":"56","author":"Malmstr\u00f6m","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2018.07.055_bib0007","unstructured":"Sanofi Pasteur. Sanofi Pasteur Statement on Discontinuation of BCG. http:\/\/www.sanofipasteur.ca\/node\/50701. Accessed January 8, 2017."},{"key":"10.1016\/j.urology.2018.07.055_bib0008","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.juro.2016.12.024","article-title":"Bacillus Calmette-Gu\u00e9rin manufacturing and SWOG S1602 intergroup clinical trial","volume":"197","author":"Meeks","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2018.07.055_bib0009","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s11934-016-0625-z","article-title":"High-risk non-muscle-invasive bladder cancer-therapy options during intravesical BCG shortage","volume":"17","author":"Veeratterapillay","year":"2016","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.urology.2018.07.055_bib0010","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.eururo.2014.11.031","article-title":"Therapeutic options in high-risk non-muscle-invasive bladder cancer during the current worldwide shortage of bacille Calmette-Gu\u00e9rin","volume":"67","author":"Mostafid","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2018.07.055_bib0011","first-page":"192","article-title":"The treatment of Ta-T1 bladder cancer in the era of worldwide BCG shortage","volume":"68","author":"Brausi","year":"2016","journal-title":"Minerva Urol Nefrol"},{"key":"10.1016\/j.urology.2018.07.055_bib0012","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1056\/NEJMp1615697","article-title":"Ensuring access to injectable generic drugs \u2013 the case of intravesical BCG for bladder cancer","volume":"376","author":"Davies","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urology.2018.07.055_bib0013","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3233\/BLC-179018","article-title":"The BCG shortage","volume":"3","author":"Messing","year":"2017","journal-title":"Bladder Cancer (Amsterdam, Netherlands)"},{"key":"10.1016\/j.urology.2018.07.055_bib0014","unstructured":"Carrol N Application of Segmented Regression Analysis to the Kaiser Permanente Colorado Critical Drug Interaction Program. http:\/\/denversug.org\/presentations\/2008CODay\/ANL-Carroll.pdf. Published 2008. Accessed January 8, 2017."},{"key":"10.1016\/j.urology.2018.07.055_bib0015","first-page":"4927","article-title":"Intravesical therapy use in the high risk patient: practice patterns in an equal access healthcare institution before and after national guidelines","volume":"16","author":"Pugliese","year":"2009","journal-title":"Can J Urol"},{"key":"10.1016\/j.urology.2018.07.055_bib0016","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1464-410X.2007.06912.x","article-title":"The increasing use of intravesical therapies for stage T1 bladder cancer coincides with decreasing survival after cystectomy","volume":"100","author":"Lambert","year":"2007","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2018.07.055_bib0017","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1002\/cncr.25007","article-title":"Patterns of care for early stage bladder cancer","volume":"116","author":"Strope","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.urology.2018.07.055_bib0018","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1200\/JOP.2011.000480","article-title":"Adjuvant intravesical bacillus calmette-gu\u00e9rin therapy and survival among elderly patients with non-muscle-invasive bladder cancer","volume":"9","author":"Spencer","year":"2013","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.urology.2018.07.055_bib0019","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1186\/1471-2407-13-332","article-title":"Optimal schedule of bacillus calmette-guerin for non-muscle-invasive bladder cancer: a meta-analysis of comparative studies","volume":"13","author":"Zhu","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.urology.2018.07.055_bib0020","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.eururo.2014.02.061","article-title":"Bacillus Calmette-Gu\u00e9rin strain differences have an impact on clinical outcome in bladder cancer immunotherapy","volume":"66","author":"Rentsch","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2018.07.055_bib0021","doi-asserted-by":"crossref","unstructured":"Hofbauer SL, Shariat SF, Chade DC, et al. The Moreau Strain of Bacillus Calmette-Guerin (BCG) for high-risk non-muscle invasive bladder cancer: an alternative during worldwide BCG shortage?Urol Int. 2016;96:46-50. doi:10.1159\/000440701.","DOI":"10.1159\/000440701"},{"key":"10.1016\/j.urology.2018.07.055_bib0022","unstructured":"Southwest Oncology Group. S1602: Different Strains of BCG With or Without Vaccine in High Grade Non-Muscle Invasive Bladder Cancer. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03091660."},{"key":"10.1016\/j.urology.2018.07.055_bib0023","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3389\/fonc.2017.00260","article-title":"Intravesical gemcitabine versus intravesical bacillus calmette-gu\u00e9rin for the treatment of non-muscle invasive bladder cancer: an evaluation of efficacy and toxicity","volume":"7","author":"Prasanna","year":"2017","journal-title":"Front Oncol"},{"key":"10.1016\/j.urology.2018.07.055_bib0024","article-title":"Intravesical gemcitabine for non-muscle invasive bladder cancer","volume":"1","author":"Jones","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.urology.2018.07.055_bib0025","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1016\/j.juro.2012.07.097","article-title":"A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer","volume":"188","author":"Burke","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2018.07.055_bib0026","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.juro.2013.03.030","article-title":"Phase I trial of intravesical recombinant adenovirus mediated interferon-\u03b12b formulated in Syn3 for Bacillus Calmette-Gu\u00e9rin failures in nonmuscle invasive bladder cancer","volume":"190","author":"Dinney","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2018.07.055_bib0027","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/nrurol.2015.58","article-title":"Expert consensus document: consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer","volume":"12","author":"Kamat","year":"2015","journal-title":"Nat Rev Urol"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429518309518?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429518309518?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T21:14:29Z","timestamp":1559078069000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429518309518"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":27,"alternative-id":["S0090429518309518"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2018.07.055","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Utilization of Bacillus Calmette-Guerin for Nonmuscle Invasive Bladder Cancer in an Era of Bacillus Calmette-Guerin Supply Shortages","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2018.07.055","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}